| Ahmad Al-khatib, MD | |
|
811 Se 28th St Ste 5, Bentonville, AR 72712-4294 | |
| (479) 254-9761 | |
| (479) 254-9762 |
| Full Name | Ahmad Al-khatib |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 33 Years |
| Location | 811 Se 28th St Ste 5, Bentonville, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548273394 | NPI | - | NPPES |
| 2227861 | Medicaid | OH | |
| 000000198168 | Other | OH | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 35078468A (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Medical Center-springdale | Springdale, AR | Hospital |
| Mercy Hospital Northwest Arkansas | Rogers, AR | Hospital |
| Washington Regional Medical Center | Fayetteville, AR | Hospital |
| Entity Name | Benton Neurocare Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063680973 PECOS PAC ID: 9739255027 Enrollment ID: O20080910000697 |
News Archive
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).
NewScientist reports on the U.S. National Science Advisory Board for Biosecurity's (NSABB) recommendation that revised versions of two controversial studies on H5N1 avian flu be published in scientific journals, reversing its previous recommendation that the studies only be published if certain details were withheld. According to the news service, dissent among the board members over the issue has prompted the committee to "propose talks to draft global guidelines for doing and communicating work involving dangerous pathogens."
Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.
Synthego, a leading provider of genome engineering solutions, officially launches today. Synthego's flagship product line, CRISPRevolution, features synthetic guide RNA products designed to accelerate CRISPR/Cas9 and Cpf1 genome engineering research. CRISPRevolution is the first product line to offer economical access to fully synthetic RNA for high fidelity editing and increased precision in genome editing.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ahmad Al-khatib, MD 811 Se 28th St Ste 5, Bentonville, AR 72712-4294 Ph: (479) 254-9761 | Ahmad Al-khatib, MD 811 Se 28th St Ste 5, Bentonville, AR 72712-4294 Ph: (479) 254-9761 |
News Archive
Pembrolizumab, an immunotherapy drug that was extensively evaluated by UCLA cancer researcher Dr. Edward Garon, has been approved by the U.S. Food & Drug Administration as first-line treatment for non-small cell lung cancer (NSCLC).
NewScientist reports on the U.S. National Science Advisory Board for Biosecurity's (NSABB) recommendation that revised versions of two controversial studies on H5N1 avian flu be published in scientific journals, reversing its previous recommendation that the studies only be published if certain details were withheld. According to the news service, dissent among the board members over the issue has prompted the committee to "propose talks to draft global guidelines for doing and communicating work involving dangerous pathogens."
Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain.
Synthego, a leading provider of genome engineering solutions, officially launches today. Synthego's flagship product line, CRISPRevolution, features synthetic guide RNA products designed to accelerate CRISPR/Cas9 and Cpf1 genome engineering research. CRISPRevolution is the first product line to offer economical access to fully synthetic RNA for high fidelity editing and increased precision in genome editing.
› Verified 9 days ago
Dr. Saadia Noreen Haneef, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2003 Se Walton Blvd., Bentonville, AR 72712 Phone: 479-464-8081 Fax: 479-464-0674 | |
Ester Arejola Salvador, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2508 Se 20th St, Bentonville, AR 72712 Phone: 479-750-2020 Fax: 479-750-4843 | |
Dr. Chaitanya Goud Bonda, M.D., MBBS Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2900 Medical Center Pkwy, Ste 310, Bentonville, AR 72712 Phone: 479-553-3310 Fax: 479-553-1947 | |
Donnie Joe Holden, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Se 22nd St Ste 14, Bentonville, AR 72712 Phone: 479-367-2552 Fax: 479-367-2584 |